Citius Oncology, Inc. (CTOR)

Every figure this model derived for CTOR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 16,563,705 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 42,707,165 AssetsCurrent 2026-06-30
current liabilities 58,787,194 LiabilitiesCurrent 2026-06-30
equity 40,384,994 StockholdersEquity 2026-06-30
interest expense 367,881 InterestExpenseNonoperating 2026-06-30
ocf -5,492,046 NetCashProvidedByUsedInOperatingActivities 2025-09-30
revenue 7,105,197 Revenues 2026-06-30
sbc 13,341,683 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CTOR on one particular measure came for.

RatioValue
cash operating margin-477.85
current ratio0.73
current ratio reported0.73
dilution pct7.67
fcf margin-77.3
interest cover-128.56
operating margin-665.63
owner earnings margin-265.07
sbc pct revenue187.77

What to be careful about

What this model itself distrusts about CTOR's figures. Written by the derivation as it ran, not added afterwards.